At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
Computed Tomography +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors
In Brief
A clinical study evaluating Computed Tomography, Fluorothymidine F-18, and 1 other intervention for Metastatic Malignant Neoplasm in the Brain and 2 related conditions. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with brain tumors. Comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm, Recurrent Brain Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedJun 2014
Primary CompletionJan 2019
TodayJul 2026
First PostedJun 18, 2014
Enrollment StartNov 1, 2012
Primary CompletionJan 21, 2019
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 12.0 years ago
Interventions
Computed Tomographyprocedure
Undergo 18F-FLT PET/CT
Fluorothymidine F-18radiation
Undergo 18F-FLT PET/CT
Positron Emission Tomographyprocedure
Undergo 18F-FLT PET/CT